retatrutide glp-1 receptor agonist Switching from tirzepatide to retatrutide: the complete transition guide Use of an unapproved triple-hormone

This study aims to comprehensively review the impact of GLP-1 RAs on various body systems, emphasizing both positive and negative effects while addressing existing knowledge gaps in the literature

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios

This is a huge market

The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity

A systematic search of PubMed, Scopus, and Web of Science was conducted up to December 2024 according to PRISMA guidelines